This is the Quild daily, highlighting one early-stage startup that has statistically significant signals of becoming a unicorn.
Entos combines machine learning and automated chemistry to revolutionize small-molecule therapeutics design. Traditional therapeutic discovery is highly complex and entails prolonged timelines, vast training data needs and sub-optimal accuracy. Entos is eradicating these challenges with its cutting-edge OrbNet platform, an AI-driven drug-development process that creates a thousand-fold acceleration in molecular properties prediction with 100x less training data required.
Founders: Thomas Miller (CEO), Fred Manby (CTO), Tim Cernak (CSO), Sarah Trice (COO), Matthew Welborn (Director)
Signals:
Top company alumni
Tim was a principal scientist at Merck for ~9 years
Sarah was a scientist and led innovation & business units at Merck for 15 years
Top university alumni, academics, and scientists
Thomas is a professor of Chemistry at CalTech. He graduated with a PhD in Theoretical Chemistry from University of Oxford, a MPhil in Theoretical Chemistry from UCL, a BS in Chemistry & Mathematics from Texas A&M, and was a postdoctoral fellow at UC Berkeley
Fred is a professor of Theoretical Chemistry at University of Bristol
Tim is an assistant professor at University of Michigan. He graduated with a PhD in Organic Chemistry from McGill University and was a postdoctoral fellow of Chemical Synthesis at Columbia University
Sarah graduated with an MBA from MIT and a PhD in Organic Chemistry from University of Pennsylvania
Matthew graduated with a PhD in Physical Chemistry from MIT and a BS in Chemistry from UT Austin. He was also a scientist at CalTech
Fast team growth
Grew 2x YoY from 21 to 43 employees
Midas list investors
Till tomorrow, Kenn
